Stockwatch: an internal examination of venture capital
This article was originally published in Scrip
These are comparatively uncomfortable times for life science venture capital (VC) investors. In the 1990s, VCs could bring a life science company to the public markets, recover their cost by divesting part of their investment at the IPO, and see their remaining holding rocket in value as generalist shareholders clamoured for the next hot biotech biotechnology IPO. A few months after the IPO, and with a little luck, many companies were also able to complete secondary offerings of stock from their VCs, CEOs and CFOs, putting most of the company’s shares in public hands.
You may also be interested in...
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.